Contract for over EUR1m with French Biotech

RNS Number : 1828D

Venn Life Sciences Holdings PLC

23 October 2015

 

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Contract for over €1m with leading French Biotech

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the signing of a project worth in excess of €1m with a leading French Biotech company.

The Phase I-II project is centred on acute T-cell leukaemia ('ATL'), and will cover multiple regions, including France (and French administered overseas territories), the UK and the US. This project will run for 33 months and follows on from a previous successful trial with the same company.

Tony Richardson, Chief Executive Officer of Venn said: "The €1m project illustrates the high standard of execution for Venn's projects and how this can be used to generate repeat customer business. We have a growing client base, a strong book of business and a clear opportunity to secure more repeat business through high performance."

Enquiries:

Venn Life Sciences Holdings Plc		www.vennlifesciences.com
Tony Richardson, Chief Executive Officer		Tel: [phone]
Jonathan Hartshorn, Chief Financial Officer		Tel: [phone]
Orla McGuinness, Marketing Manager		Tel: [phone]
Zeus Capital (Nominated Adviser and Co-Broker)
Andrew Jones/Phil Walker		Tel: [phone]
Dominic Wilson/Alex Davies		Tel : [phone]
Hybridan LLP (Co-Broker)
Claire Louise Noyce		Tel: [phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus		Mob: [phone]
Lianne Cawthorne		Mob: [phone]

About Venn Life Sciences Limited:

Venn is a full service European Contract Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation, Venn specialises in both national and European-wide Phase II-Phase IV multi-site trials with extensive expertise in EU regulations, therapeutic areas and local languages. Over a 25 year history, Venn has built up substantial study experience, contributing to the efficient management of sites, budgets and communication channels with all parties involved. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science. In October 2015 Venn completed the acquisition of Kinesis Pharma BV, highly differentiating Venn within the CRO market as it can now offer services from early clinical/non-clinical evaluation through to Phase IV. This deepens its service capability and enables Venn to offer a complete end-to-end service.

 

 

END

 

 

MSCUURNRVKARUAA